Selected Publications
Selection is based on our experimental projects and involvement of our laboratories.
Regarding publications of the
Dept. of Surgery, CCM|CVK, (in particular clinical projects) we would like to refer to Medline.

Title - Change Me

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. 

Back

Title - Change Me

Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival
Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. 

Gastrointest Oncol. 2016;8(3)
Back

Title - Change Me

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment
Striefler JK, Sinn M, Pelzer U, Jühling A, Wislocka L, Bahra M, Sinn BV, Denkert C, Dörken B, Oettle H, Riess H, Bläker H, Lohneis P.

Back

Title - Change Me

Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial
Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M, Wilhelm TJ, Farkas SA, Börner T, Bruns C, Kleespies A, Kleeff J, Mihaljevic AL, Uhl W, Chromik A, Fendrich V, Heeger K, Padberg W, Hecker A, Neumann UP, Junge K, Kalff JC, Glowka TR, Werner J, Knebel P, Piso P, Mayr M, Izbicki J, Vashist Y, Bronsert P, Bruckner T, Limprecht R, Diener MK, Rossion I, Wegener I, Hopt UT.

Back

Title - Change Me

Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P.

Back

Title - Change Me

Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival
Kamphues C, Bova R, Bahra M, Klauschen F, Muckenhuber A, Sinn BV, Warth A, Goeppert B, Endris V, Neuhaus P, Weichert W, Stenzinger A.

Back

Title - Change Me

Cytoreductive Surgery for Pancreatic Cancer improves Overall Outcome of Gemcitabine-Based Chemotherapy
Bahra M, Pratschke J, Klein F, Neuhaus P, Boas-Knoop S, Puhl G, Denecke T, Pullankavumkal JR, Sinn M, Riess H, Pelzer U.

Back

Title - Change Me

CT and MRI Findings of Autoimmune Polymorph Bifocal Pancreatitis Mimicking Pancreatic Adenocarcinoma: A Case Report and Review of the Literature
Rotzinger R, Bläker H, Bahra M, Denecke T, Grieser C.

Back

Title - Change Me

CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation
N. Raschzok, A. Reutzel-Selke, R.B. Schmuck, M.H. Morgul, U. Gauger,K.A. Prabowo, L.-M. Tannus, A. Leder, B. Struecker, S. Boas-Knoop, M. Bartels, S. Jonas, Ch. Lojewski, G. Puhl, D. Seehofer, M. Bahra, A. Pascher, J. Pratschke, I.M. Sauer

Back

Title - Change Me

Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer
Andreou A, Viganò L, Zimmitti G, Seehofer D, Dreyer M, Pascher A, Bahra M, Schoening W, Schmitz V, Thuss-Patience PC, Denecke T, Puhl G, Vauthey JN, Neuhaus P, Capussotti L, Pratschke J, Schmidt SC.

Back

Title - Change Me

Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy
Sinn M, Ganeshan R, Graf R, Pelzer U, Stieler JM, Striefler JK, Bahra M, Wust P, Riess H.

Back

Title - Change Me

DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study
Kamphues C, Al-Abadi N, Dürr A, Bova R, Klauschen F, Stenzinger A, Bahra M, Al-Abadi H, Neuhaus P, Seehofer D.

Back

Title - Change Me

Significant impact of patient age on outcome after liver resection for HCC in cirrhosis
Faber W, Stockmann M, Schirmer C, Möllerarnd A, Denecke T, Bahra M, Klein F, Schott E, Neuhaus P, Seehofer D.

Back

Title - Change Me

Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial
Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, RiessPelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess

Back

Title - Change Me

Hedgehog pathway as a potential treatment target in human cholangiocarcinoma
Riedlinger D, Bahra M, Boas-Knoop S, Lippert S, Bradtmöller M, Guse K, Seehofer D, Bova R, Sauer IM, Neuhaus P, Koch A, Kamphues C.

Back

Title - Change Me

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma
Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H. 

Back

Title - Change Me

Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas
Riener MO, Thiesler T, Hellerbrand C, Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W, Terracciano L, Kristiansen G. 

Back

Title - Change Me

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H, Sinn BV.

Back

Title - Change Me

Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy
Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H.

Back

Title - Change Me

Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study
Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H.

Back

Title - Change Me

Morphological analysis and differentiation of benign cystic neoplasms of the pancreas using computed tomography and magnetic resonance imaging
Grieser C, Heine G, Stelter L, Steffen IG, Rothe JH, Walter TC, Fischer C, Bahra M, Denecke T.

Back

Title - Change Me

DNA Index as a Strong Prognostic Factor in Patients with Adenocarcinoma of the Pancreatic Head: Results of a 5-Year Prospective Study
Kamphues C, Al-Abadi H, Dürr A, Al-Abadi N, Schricke D, Bova R, Müller V, Stenzinger A, Klauschen F, Seehofer D, Neuhaus P, Bahra M.

Back

Title - Change Me

Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer
Kamphues C, Wittschieber D, Klauschen F, Kasajima A, Dietel M, Schmidt SC, Glanemann M, Bahra M, Neuhaus P, Weichert W, Stenzinger A.

Back

Title - Change Me

Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas
Bahra M, Kamphues C, Boas-Knoop S, Lippert S, Esendik U, Schüller U, Hartmann W, Waha A, Neuhaus P, Heppner F, Pietsch T, Koch A.

Back

Title - Change Me

Postoperative complications deteriorate long-term outcome in pancreatic cancer patients
Kamphues C, Bova R, Schricke D, Hippler-Benscheidt M, Klauschen F, Stenzinger A, Seehofer D, Glanemann M, Neuhaus P, Bahra M.

Back

Title - Change Me

Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy
Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, Neumann U, Seehofer D.

Back

Title - Change Me

High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer
Klauschen F, von Winterfeld M, Stenzinger A, Sinn BV, Budczies J, Kamphues C, Bahra M, Wittschieber D, Weichert W, Striefler J, Riess H, Dietel M, Denkert C.

Back

Title - Change Me

Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma
Kamphues C, Seehofer D, Collettini F, Bahra M, Neuhaus P, Wust P, Denecke T, Gebauer B, Schnapauff D.

Back

Title - Change Me

Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes
Winter C, Kristiansen G, Kersting S, Roy J, Aust D, Knösel T, Rümmele P, Jahnke B, Hentrich V, Rückert F, Niedergethmann M, Weichert W, Bahra M, Schlitt HJ, Settmacher U, Friess H, Büchler M, Saeger HD, Schroeder M, Pilarsky C, Grützmann R.

Back

Title - Change Me

Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma
Eurich D, Boas-Knoop S, Morawietz L, Neuhaus R, Somasundaram R, Ruehl M, Neumann UP, Neuhaus P, Bahra M, Seehofer D.

Back

Title - Change Me

Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas
Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G.

Back

Title - Change Me

Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas
Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G.

Back

Title - Change Me

Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas
Riener MO, Stenner F, Liewen H, Hellerbrand C, Bahra M, Kristiansen G.

Back

Title - Change Me

Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases
Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R, Neuhaus P.

Back

Title - Change Me

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro in vivo
Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Müller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W.

Back

Title - Change Me

Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes
Schumacher G, Hoffmann J, Cramer T, Spinelli A, Jacob D, Bahra M, Pratschke J, Pfitzmann R, Schmidt S, Lage H.

Back

Title - Change Me

Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times
Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C.

Back

Title - Change Me

Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth
Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, Rueggeberg A, Neuhaus R, Bahra M, Jacob D, Gerlach H, Neuhaus P.

Back

This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purpose illustrated in the Disclaimer. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.